Biogen Inc. took a colossal risk in late 2019. It revived a drug for Alzheimer’s disease it had left for dead earlier that year after the medication appeared to fail two large clinical trials.
The company wasn’t ready to take no for an answer. Biogen, along with its Tokyo-based partner Eisai Co. Ltd., had poured years of effort into developing the therapy, then called aducanumab, and was counting on it as its next big therapeutic advance.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.
We humbly apologize for the inconvenience.